Nanologica Q1 2024: Mixed start of the year - Redeye
Redeye returns with an updated view on Nanologica following its Q1 report. Sales and EBIT was softer than our estimates, but the company reported its highest quarterly chromatography sales to date. We somewhat lower our base case.
ANNONS
Redeye returns with an updated view on Nanologica following its Q1 report. Sales and EBIT was softer than our estimates, but the company reported its highest quarterly chromatography sales to date. We somewhat lower our base case.